Latest news with #NRCIRAP
Yahoo
22-05-2025
- Health
- Yahoo
Medirex receives funding to modernise patient authentication
Healthcare technology company Medirex Systems has secured funding for patient authentication from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). Medirex received NRC IRAP's advisory services and research and development financing to support a project designed to improve patient authentication in healthcare environments. The initiative led by the company uses its expertise by adding a digital element, transforming the conventional hospital wristband into a secure portal for accessing personal health information. The patent-pending technology begins with verifying the identity in person and issuing a wristband, which then allows the patient to establish a secure link to external systems. This approach eliminates the need for hospital staff to access or handle data beyond their duties. Central to this project is the standards-compliant identity and authentication interface, Medirex Open API, which permits patients to authorise third-party applications, such as remote patient monitoring (RPM) systems. Through this authorisation, they can access their health-related information from electronic health record (EHR) systems such as Oracle and Epic. This API facilitates the sharing of identity and essential data required to register and use external systems, all while maintaining patient privacy and control. The Medirex Patient Authentication API facilitates the secure management of health information for patients across various care settings, ranging from hospital admissions to domestic monitoring systems. Patients can scan their wristband and confirm their identity through text message or email, and grant access to their records either for themselves or for approved digital health instruments such as RPM systems. This method tackles the challenge of maintaining data confidentiality while meeting the demands of external care collaborators. Medirex's solution delineates clear access roles, ensuring that only the relevant individuals can access the essential data, with the patient's permission. Medirex managing director Mark Caskenette said: "By enabling a secure, patient-led handoff from the hospital wristband to third-party tools, we ensure that care can extend beyond the hospital without compromising privacy or involving staff in unnecessary data access." "Medirex receives funding to modernise patient authentication" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
21-05-2025
- Health
- Cision Canada
Medirex announces funding support for innovative healthcare solution
TORONTO, May 21, 2025 /CNW/ - Medirex Systems Inc. is pleased to announce that it received advisory services and research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support a breakthrough project aimed at modernizing patient authentication in healthcare settings. This project builds on Medirex's trusted expertise in patient identification by introducing a new digital layer that transforms the traditional hospital wristband into a gateway for secure, verified access to personal health information. The solution, which is patent-pending, begins with in-person identity confirmation and the issuance of a wristband — enabling patients to initiate a secure connection from the hospital wristband to external systems without requiring hospital staff to manage or access data outside their responsibilities. At the core of this project is the Medirex Open API, a standards-based identity and authentication bridge that allows patients to authorize third-party applications — such as RPM systems — to access their health data from Electronic Health Record (EHR) systems like Epic and Oracle. Rather than sharing full medical records or giving hospital staff unnecessary access, the API enables patients to share only the identity and essential data needed to register and use external systems. This process begins with in-person verification and wristband issuance, and puts the patient fully in control — ensuring privacy, precision, and consent are at the center of every connection. The Medirex Patient Authentication API empowers patients to securely control access to their data across care settings — from hospital visits to at-home monitoring — while upholding the highest standards of privacy and security. By scanning their wristband and confirming their identity via SMS or email, patients can authorize access for themselves or for approved digital health tools such as RPM systems. This innovation directly addresses a key challenge in healthcare today: balancing data privacy with the needs of third-party care partners. Hospital staff do not always require access to the same data needed by external RPM providers or family caregivers. Medirex's solution creates a clear separation of access roles, ensuring that only the right stakeholders can see the right information — with patient consent at the center. "We're building on what hospitals already trust — the wristband — and adding a secure, patient-friendly way to unlock digital access," said Mark Caskenette, Managing Director at Medirex. "By enabling a secure, patient-led handoff from the hospital wristband to third-party tools, we ensure that care can extend beyond the hospital without compromising privacy or involving staff in unnecessary data access. Thanks to NRC IRAP's support, we're delivering a platform that protects patient privacy while expanding how and where care can be delivered." This project supports Medirex's mission to make healthcare more connected, transparent, and patient-centered. By combining physical identity verification with secure digital consent, Medirex is helping shape a healthcare ecosystem where patients are both empowered and protected. The project marks a significant milestone in Medirex's journey to becoming a leader in digital health solutions. By leveraging the support of NRC IRAP, Medirex is poised to set new standards in patient engagement and healthcare delivery through this API and its digital health platform, mySPOT. For more information about Medirex and patient authentication, please visit: About Medirex Systems Inc. Medirex Systems Inc. is a Canadian healthcare technology company specializing in patient identification and digital health innovation. With a strong focus on patient safety, secure data access, interoperability, and 360° patient engagement, Medirex develops technologies that help healthcare organizations deliver better, more responsive care. SOURCE Medirex Systems Inc.
Yahoo
21-05-2025
- Health
- Yahoo
Medirex announces funding support for innovative healthcare solution
TORONTO, May 21, 2025 /CNW/ - Medirex Systems Inc. is pleased to announce that it received advisory services and research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support a breakthrough project aimed at modernizing patient authentication in healthcare settings. This project builds on Medirex's trusted expertise in patient identification by introducing a new digital layer that transforms the traditional hospital wristband into a gateway for secure, verified access to personal health information. The solution, which is patent-pending, begins with in-person identity confirmation and the issuance of a wristband — enabling patients to initiate a secure connection from the hospital wristband to external systems without requiring hospital staff to manage or access data outside their responsibilities. At the core of this project is the Medirex Open API, a standards-based identity and authentication bridge that allows patients to authorize third-party applications — such as RPM systems — to access their health data from Electronic Health Record (EHR) systems like Epic and Oracle. Rather than sharing full medical records or giving hospital staff unnecessary access, the API enables patients to share only the identity and essential data needed to register and use external systems. This process begins with in-person verification and wristband issuance, and puts the patient fully in control — ensuring privacy, precision, and consent are at the center of every connection. The Medirex Patient Authentication API empowers patients to securely control access to their data across care settings — from hospital visits to at-home monitoring — while upholding the highest standards of privacy and security. By scanning their wristband and confirming their identity via SMS or email, patients can authorize access for themselves or for approved digital health tools such as RPM systems. This innovation directly addresses a key challenge in healthcare today: balancing data privacy with the needs of third-party care partners. Hospital staff do not always require access to the same data needed by external RPM providers or family caregivers. Medirex's solution creates a clear separation of access roles, ensuring that only the right stakeholders can see the right information — with patient consent at the center. "We're building on what hospitals already trust — the wristband — and adding a secure, patient-friendly way to unlock digital access," said Mark Caskenette, Managing Director at Medirex. "By enabling a secure, patient-led handoff from the hospital wristband to third-party tools, we ensure that care can extend beyond the hospital without compromising privacy or involving staff in unnecessary data access. Thanks to NRC IRAP's support, we're delivering a platform that protects patient privacy while expanding how and where care can be delivered." This project supports Medirex's mission to make healthcare more connected, transparent, and patient-centered. By combining physical identity verification with secure digital consent, Medirex is helping shape a healthcare ecosystem where patients are both empowered and protected. The project marks a significant milestone in Medirex's journey to becoming a leader in digital health solutions. By leveraging the support of NRC IRAP, Medirex is poised to set new standards in patient engagement and healthcare delivery through this API and its digital health platform, mySPOT. For more information about Medirex and patient authentication, please visit: About Medirex Systems Systems Inc. is a Canadian healthcare technology company specializing in patient identification and digital health innovation. With a strong focus on patient safety, secure data access, interoperability, and 360° patient engagement, Medirex develops technologies that help healthcare organizations deliver better, more responsive care. View original content: SOURCE Medirex Systems Inc. View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
ME Therapeutics Receives Support to Advance mRNA Therapeutic Candidates for Cancer and Inflammatory Disease
VANCOUVER, British Columbia, May 21, 2025--(BUSINESS WIRE)--ME Therapeutics Holdings Inc. ("ME Therapeutics" or the "Company") (CSE: METX) (FSE: Q9T), a publicly listed preclinical biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, today announced that its subsidiary, ME Therapeutics Inc., is receiving advisory services and up to $140,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The project will support the research and development of ME Therapeutic's mRNA therapeutic program targeting myeloid cell biology for the treatment of cancer and inflammatory disease. "We are pleased to receive this support from NRC IRAP, which builds on advisory services and funding received in past years, to allow us to further advance preclinical studies for our mRNA therapeutic candidates that target key myeloid cell pathways," said Salim Dhanji, CEO of ME Therapeutics. "Our team at ME Therapeutics passionately believes myeloid cell-derived mRNA therapies represent the next wave of treatments for patients with cancer and inflammatory disease who today have limited treatment options, and we are committed to bringing these potential new approaches to the clinic as soon as possible." ME Therapeutics's proprietary mRNA sequences have been engineered to encode for proteins that can modify the immune response in vivo in a targeted manner. Their lead mRNA therapeutic candidate is specifically designed to modulate immune cells in the tumour microenvironment and stimulate an anti-cancer immune response. Preclinical testing has already demonstrated encouraging anti-cancer activity in a mouse model of colorectal cancer. In addition, ME Therapeutics is exploring design modifications of its mRNA candidates to modulate mRNA expression in a tissue-specific manner for increased efficacy and safety. About ME Therapeutics Myeloid Enhancement (ME) Therapeutics is a publicly listed, preclinical stage biotechnology company based in Vancouver involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer. Our focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells to enhance anti-cancer immunity. For more information, visit Neither the Canadian Securities Exchange nor any Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement Regarding Forward-Looking Statements This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements in this news release include, but are not limited to, statements regarding the Company's collaborations, research plans, the timing for completion of studies and the receipt of results, the intended outcomes of the research, the intended benefits and applications of the Company's technology, and the Company's plans for development of its business. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including risks related to factors beyond the control of the Company, that the results of the testing are not favorable, that future research does not support continued development, that regulatory approvals are not obtained or maintained, that challenges related to mRNA technology development, including delivery, stability, or efficacy issues cannot be overcome, that the Company relies on third-party collaborators and vendors for certain aspects of the research, that the research will not be completed within the expected timeline, that the Company is unable to obtain intellectual property protection for the results, that the Company may require additional funding to advance its research and develop its business, and that the Company's business may not develop as set out in this news release. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ from forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. View source version on Contacts Media Claire PiechMagnetic Communicationsclaire@ +1-604-698-6637
National Post
21-05-2025
- Business
- National Post
ME Therapeutics Receives Support to Advance mRNA Therapeutic Candidates for Cancer and Inflammatory Disease
Article content VANCOUVER, British Columbia — ME Therapeutics Holdings Inc. ('ME Therapeutics' or the 'Company') (CSE: METX) (FSE: Q9T), a publicly listed preclinical biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, today announced that its subsidiary, ME Therapeutics Inc., is receiving advisory services and up to $140,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The project will support the research and development of ME Therapeutic's mRNA therapeutic program targeting myeloid cell biology for the treatment of cancer and inflammatory disease. Article content Article content 'We are pleased to receive this support from NRC IRAP, which builds on advisory services and funding received in past years, to allow us to further advance preclinical studies for our mRNA therapeutic candidates that target key myeloid cell pathways,' said Salim Dhanji, CEO of ME Therapeutics. 'Our team at ME Therapeutics passionately believes myeloid cell-derived mRNA therapies represent the next wave of treatments for patients with cancer and inflammatory disease who today have limited treatment options, and we are committed to bringing these potential new approaches to the clinic as soon as possible.' Article content ME Therapeutics's proprietary mRNA sequences have been engineered to encode for proteins that can modify the immune response in vivo in a targeted manner. Their lead mRNA therapeutic candidate is specifically designed to modulate immune cells in the tumour microenvironment and stimulate an anti-cancer immune response. Preclinical testing has already demonstrated encouraging anti-cancer activity in a mouse model of colorectal cancer. In addition, ME Therapeutics is exploring design modifications of its mRNA candidates to modulate mRNA expression in a tissue-specific manner for increased efficacy and safety. Article content About ME Therapeutics Article content Myeloid Enhancement (ME) Therapeutics is a publicly listed, preclinical stage biotechnology company based in Vancouver involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer. Our focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells to enhance anti-cancer immunity. For more information, visit Article content Neither the Canadian Securities Exchange nor any Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Article content This news release includes certain 'forward-looking statements' under applicable Canadian securities legislation. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements in this news release include, but are not limited to, statements regarding the Company's collaborations, research plans, the timing for completion of studies and the receipt of results, the intended outcomes of the research, the intended benefits and applications of the Company's technology, and the Company's plans for development of its business. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including risks related to factors beyond the control of the Company, that the results of the testing are not favorable, that future research does not support continued development, that regulatory approvals are not obtained or maintained, that challenges related to mRNA technology development, including delivery, stability, or efficacy issues cannot be overcome, that the Company relies on third-party collaborators and vendors for certain aspects of the research, that the research will not be completed within the expected timeline, that the Company is unable to obtain intellectual property protection for the results, that the Company may require additional funding to advance its research and develop its business, and that the Company's business may not develop as set out in this news release. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ from forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Article content Article content Article content Article content Contacts Article content Article content Article content
